<p>Thioridazine is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic&nbsp;drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with thioridazine treatment, thioridazine should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an&nbsp;effective dose&nbsp;due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine, it is strongly recommended that a patient be given at least 2 trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration.<br />
<br />
However, the prescriber should be aware that thioridazine has not been systematically evaluated in controlled trials in treatment refractory&nbsp;schizophrenic patients and its efficacy in such patients is unknown.</p>